BREDIS Healthcare Named Asia's First Certified Service Provider by Alamar Biosciences, Accelerating Global Precision Medicine Proteomics Push

In the global liquid biopsy and precision medicine markets, the importance of ultra-sensitive biomarker analysis data for early disease prediction is rising rapidly. Competitions to secure global standard analysis infrastructures are intensifying, particularly in drug discovery and clinical trials for diseases like cancer and neurodegenerative disorders that require tracking minute changes in protein levels. Amid this trend, a South Korean precision medicine platform company is drawing attention from the data healthcare market by officially joining a leading global technology provider as its first official service partner in Asia.

Bredis Healthcare, a company specializing in ultra-sensitive biomarker analysis, announced that it has been selected as a 'Certified Service Provider (CSP)'—the highest-tier service partner program of Alamar Biosciences, a leading US-based precision proteomics company. This selection marks the first of its kind not only in South Korea but across the entire Asian region, serving as a proactive milestone that officially recognizes Bredis Healthcare’s global standard proteomic analysis capabilities and high-quality data production infrastructure.

■ Meeting Strict Global Quality Standards: Leaping into Asia’s Precision Medicine Data Hub

Alamar Biosciences’ CSP is a highly selective certification awarded only to institutions equipped with extensive experience in micro-immunoassay, sample processing expertise, and dedicated cleanroom environments and manuals that comply with Good Laboratory Practice (GLP) and Good Clinical Laboratory Practice (GCLP) standards. It is understood that Bredis Healthcare cleared these stringent screening barriers thanks to its analysis architecture and validated Quality Control (QC) data systems, which fully comply with the International Council for Harmonisation (ICH) guidelines.

By securing this technical stack, Bredis Healthcare has officially established the ultra-sensitive data reproducibility required by global multinational pharmaceutical companies, major hospitals, and national research institutions. Furthermore, by integrating its advanced precision analysis pipelines with global research hubs such as the National University of Singapore (NUS), the company is expected to solidify its position as an Asia-Pacific bio-data hub.

■ Implementing the NULISA™ Platform: Advancing 'Multimodal AI' Precision Medicine with Micro-Volume Samples

The core technological asset of this collaboration, 'NULISA™', is a breakthrough platform that simultaneously delivers ultra-sensitive detection at the attomolar and femtogram (fg/mL) levels while offering high-multiplexing capabilities, overcoming the sensitivity limitations of conventional proteomic technologies. With a micro-volume blood sample of only 50 microliters (μL), it can simultaneously and quantitatively analyze hundreds to thousands of protein biomarkers associated with neurological disorders like Alzheimer’s, inflammation, and oncology in real time.

The company plans to fully launch analytical services utilizing the NULISA™ platform for both domestic and global pharmaceutical and biotech sectors. Concurrently, it will integrate its proprietary digital biomarkers, lifelog data, and AI-based omics data analysis technologies. This integration is projected to drive the evolution of a 'next-generation multimodal precision medicine platform' that cross-analyzes various types of clinical metrics using a machine-learning engine.

Hyundoo Hwang, CEO of Bredis Healthcare, stated regarding this global certification that it is a remarkable achievement showing the company's analytical quality control system has gained trust at a world-class level. He added that by supplying high-quality proteomic data, Bredis Healthcare will leap forward as an optimal global partner to shorten drug discovery timelines and realize customized precision medicine.

Source: Korea Data Economy Daily (https://www.dataeconomy.co.kr)